Neko Health Raises $700M to Bring Its AI Body Scanner to America

Mark Zuckerberg and Priscilla Chan just wrote a check to a health-tech startup that scans the body for signs of skin cancer, cardiovascular disease, and diabetes in under an hour. They weren't alone: tennis star Maria Sharapova, musician will.i.am, and footballer Thierry Henry also joined Neko Health's newly closed $700 million Series C, one of the largest rounds in digital health this year.

Lightspeed Venture Partners led the round, with O.G. Venture Partners co-leading. Returning backers Atomico, General Catalyst, and Lakestar came back for another round, while Liberty City Ventures, Positive Sum, and BDT & MSD signed on as new institutional investors. Alexis Ohanian, an existing individual backer, also remains on the cap table. As part of the deal, David Ofer of O.G. Venture Partners is set to join Neko's board, pending regulatory clearance.

What the scan actually does

Neko Health's core product is a 60-minute, radiation-free body scan built around AI-driven imaging and diagnostics. The company positions it as a preventative screening tool rather than a diagnostic replacement for a doctor, aimed at catching early indicators of conditions like skin cancer, cardiovascular disease, and diabetes before symptoms appear. The company currently runs eight clinics across Sweden and the UK, where a scan costs 2,750 Swedish kronor (about $285) or £299, depending on location.

The fresh capital will fund Neko's first US clinic, opening in New York, marking the company's entry into the American market and its biggest geographic bet to date.

A fast-moving cap table

This Series C caps a rapid fundraising climb for the Stockholm-founded company. Neko Health raised a $65 million Series A in 2023, followed by a $260 million round in January 2025. With the new $700 million injection, the company's disclosed funding since 2023 now exceeds $1 billion, an unusually steep trajectory for a startup still operating fewer than a dozen physical locations.

That pace of capital raising, paired with the celebrity and Big Tech names attached to the round, signals investor appetite for consumer-facing preventative health services that lean on AI for screening at scale. It also raises the stakes for Neko's US launch: entering the American healthcare market means navigating a far more fragmented regulatory and insurance landscape than the company has faced in Sweden or the UK, where its clinics operate largely as out-of-pocket wellness services rather than insurance-billed medical procedures.

Whether Neko can replicate its European pricing and clinic model in New York, where real estate, staffing, and compliance costs run considerably higher, will be the first real test of whether this valuation and funding pace are justified beyond the buzz of its investor list.